Reasons for non-treatment of hepatitis C in veterans in care

被引:73
作者
Butt, AA
Wagener, M
Shakil, AO
Ahmad, J
机构
[1] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA 15260 USA
[2] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
[3] Univ Pittsburgh, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA
[4] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA
关键词
hepatitis C; treatment; veterans; adherence; viral hepatitis;
D O I
10.1111/j.1365-2893.2005.00547.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We prospectively studied 354 patients with hepatitis C virus (HCV) infection who were referred to a hepatology specialty clinic to find the reasons for non-treatment of HCV. The median age was 48 years (range 27-77 years), 98.5% were male and 71% were white. Seventy per cent of the patients were not treated. The most common reasons for non-treatment were non-adherence to follow-up visit (24%), normal liver enzymes (14%), concurrent medical problems (11%), alcohol and drug use (9%), psychiatric problems (7%), advanced liver disease (7%), referral for transplant evaluation (6.4%) and patient refusal, transfer of care to another facility and non-detectable HCV RNA levels (5% each). The reason was not recorded for 5% of the patients and was treatment deferred in 2.4% while waiting for pegylated interferon approval. Non-treatment was more likely in patients with less than 12 years of education and a history of incarceration. Patients who were lost to follow-up and refused treatment were more likely to have current alcohol and drug use and a history of incarceration.
引用
收藏
页码:81 / 85
页数:5
相关论文
共 16 条
[1]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[2]   Prevalence of hepatitis C virus seropositivity among hospitalized US veterans [J].
Austin, GE ;
Jensen, B ;
Leete, J ;
De L'Aune, W ;
Bhatnagar, J ;
Racine, M ;
Braun, JE .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2000, 319 (06) :353-359
[3]   Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis B virus infection [J].
Baffis, V ;
Shrier, I ;
Sherker, AH ;
Szilagyi, A .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (09) :696-701
[4]   Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration Medical Center [J].
Briggs, ME ;
Baker, C ;
Hall, R ;
Gaziano, JM ;
Gagnon, D ;
Bzowej, N ;
Wright, TL .
HEPATOLOGY, 2001, 34 (06) :1200-1205
[5]   Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C [J].
Bruno, S ;
Battezzati, PM ;
Bellati, G ;
Manzin, A ;
Maggioni, M ;
Crosignani, A ;
Borzio, M ;
Solforosi, L ;
Morabito, A ;
Ideo, G ;
Podda, M .
JOURNAL OF HEPATOLOGY, 2001, 34 (05) :748-755
[6]   Viral hepatitis and other infectious diseases in a homeless population [J].
Cheung, RC ;
Hanson, AK ;
Maganti, K ;
Keeffe, EB ;
Matsui, SM .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 34 (04) :476-480
[7]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[8]   Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection [J].
Fultz, SL ;
Justice, AC ;
Butt, AA ;
Rabeneck, L ;
Weissman, S ;
Rodriguez-Barradas, M .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) :1039-1046
[9]   Prevalence and incidence of hepatitis C virus infection among young adult injection drug users [J].
Garfein, RS ;
Doherty, MC ;
Monterroso, ER ;
Thomas, DL ;
Nelson, KE ;
Vlahov, D .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1998, 18 :S11-S19
[10]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965